Infective endocarditis post-transcatheter aortic valve implantation (TAVI), microbiological profile and clinical outcomes: A systematic review

Autoři: Adnan Khan aff001;  Aqsa Aslam aff001;  Khawar Naeem Satti aff002;  Sana Ashiq aff001
Působiště autorů: Sharif Medical and Dental College, Lahore, Pakistan aff001;  Senior Registrar Rawalpindi Institute of Cardiology, Rawalpindi, Pakistan aff002
Vyšlo v časopise: PLoS ONE 15(1)
Kategorie: Research Article



The data on infective endocarditis after transcatheter aortic valve implantation (TAVI) is scarce and limited to case reports and case series in the literature. It is the need of the hour to analyze the available data on post-TAVI infective endocarditis from the available literature. The objectives of this systematic review were to evaluate the incidence of infective endocarditis after transcatheter aortic valve implantation, its microbiological profile and clinical outcomes. It will help us to improve the antibiotic prophylaxis strategies and treatment options for infective endocarditis in the context of TAVI.


EMBASE, Medline and the CENTRAL trials registry of the Cochrane Collaboration were searched for articles on infective endocarditis in post-TAVI patients till October 2018. Eleven articles were included in the systematic review. The outcomes assessed werethe incidence of infective endocarditis, its microbiological profile andclinical outcomes including major adverse cardiac event (MACE), net adverse clinical event (NACE), surgical intervention and valve-in-valve procedure.


The incidence of infective endocarditis varied from 0%-14.3% in the included studies, the mean was3.25%. The average duration of follow-up was 474 days (1.3 years). Enterococci were the most common causative organism isolated from 25.9% of cases followed by Staphylococcus aureus (16.1%) and coagulase-negative Staphylococcus species (14.7%). The mean in-hospital mortality and mortality at follow-up was 29.5% and 29.9%, respectively. The cumulative incidence of heart failure, stroke and major bleeding were 37.1%, 5.3% and 11.3%,respectively. Only a single study by Martinez-Selles et al. reported arrhythmias in 20% cases. The septic shock occurred in 10% and 27.7% post-TAVI infective endocarditis patients according to 2 studies. The surgical intervention and valve-in-valve procedure were reported in 11.4% and 6.4% cases, respectively.


The incidence of post-TAVI infective endocarditis is low being 3.25% but it is associated with high mortality and complications. The most common complication is heart failure with a cumulative incidence of 37.1%. Enterococciare the most common causative organism isolated from 25.9% of cases followed by Staphylococcus aureus in 16.1% of cases. Appropriate measures should be taken to prevent infective endocarditis in post-TAVI patients including adequate antibiotics prophylaxis directed specifically against these organisms.

Study registration

PROSPERO registration number CRD42018115943.

Klíčová slova:

Antibiotics – Endocarditis – Enterococcus – Enterococcus infections – Staphylococcal infection – Streptococcal infections – Surgical and invasive medical procedures – Systematic reviews


1. Ambrosioni J, Hernandez-Meneses M, Tellez A, Pericas J, Falces C, Tolosana J, et al. The changing epidemiology of infective endocarditis in the twenty-first century. Curr Infect Dis Rep.2017 May 12;19(5):21. Available from: doi: 10.1007/s11908-017-0574-9 28401448

2. Duval X, Delahaye F, Alla F, Tattevin P, Obadia JF, Le Moing V, et al. Temporal trends in infective endocarditis in the context of prophylaxis guideline modifications: three successive population-based surveys. J Am Coll Cardiol. 2012 May. 29;59(22):1968–76. Available from: doi: 10.1016/j.jacc.2012.02.029 22624837

3. Murray CJL, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the global burden of disease study 2010. Lancet.2012 Dec 15;380(9859):219–23. Available from:

4. Dayer MJ, Jones S, Prendergast B, Baddour LM, Lockhart PB, Thornhill MH, et al. An increase in the incidence of infective endocarditis in England since 2008: a secular trend interrupted time series analysis. Lancet. 2015;385(9974):1219–28. Available from: doi: 10.1016/S0140-6736(14)62007-9 25467569

5. de Sa DDC, Tleyjeh IM, Anavekar NS, Schultz JC, Thomas JM, Lahr BD, et al. Epidemiological trends of infective endocarditis: a population-based study in Olmsted County, Minnesota. Mayo Clin Proc.2010 May;85(5):422–6. Available from: doi: 10.4065/mcp.2009.0585 20435834

6. Kiefer T, Park L, Tribouilloy C, Cortes C, Casillo R, Chu V, et al. Association between valvular surgery and mortality among patients with infective endocarditis complicated by heart failure. JAMA.2011 Nov 23;306(20):2239–47.Available from: doi: 10.1001/jama.2011.1701 22110106

7. Baddour LM, Wilson WR, Bayer AS, Fowler VG, Tleyjeh IM, Rybak MJ, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications. A scientific statement for healthcare professionals from the AmericanHeart Association. Circulation.2015 Oct 13;132(15):1435–86. Available from: doi: 10.1161/CIR.0000000000000296 26373316

8. Habib G, Hoen B, Tornos P, Thuny F, Prendergast B, Vilacosta I, et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the task force on the prevention, diagnosis, and treatment of infective endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for infection and cancer. Eur Heart J.2009 Oct 1;30(19):2369–413. Available from: doi: 10.1093/eurheartj/ehp285 19713420

9. van Kesteren F, Wiegerinck EMA, Rizzo S, Baan J, Planken RN, von der Thusen JH, et al. Autopsy after transcatheter aortic valve implantation. Virchows Arch.2017 Mar 27;470(3):331–9. Available from: doi: 10.1007/s00428-017-2076-4 28130699

10. Alatawi FO, Abuelatta RA, Alahmedi AB, Alharbi IH, Alghamdi SS, Sakrana AA, et al. Clinical outcomes with transcatheter aortic valve implantation at a single cardiac center in Saudi Arabia. Ann Saudi Med.2018;38(3):167–73. Available from: doi: 10.5144/0256-4947.2018.167 29848933

11. Phan K, Wong S, Phan S, Ha H, Qian P, Yan TD. Transcatheter aortic valve implantation (TAVI) in patients with bicuspid aortic valve stenosis—systematic review and meta-analysis. Heart Lung Circ.2015 Jul 1;24(7):649–59. Available from: doi: 10.1016/j.hlc.2014.12.163 25818374

12. Head SJ, Dewey TM, Mack MJ. Fungal endocarditis after transfemoral aortic valve implantation. Catheter Cardiovasc Interv.2011 Dec 1;78(7):1017–9. Available from: doi: 10.1002/ccd.23038 21547997

13. Adams DH, Popma JJ, Reardon MJ, Yakubov SJ, Coselli JS, Deeb GM, et al. Transcatheter aortic valve replacement with a self-expanding prosthesis. N Engl J Med. 2014 May 8;370(19):1790–8. Available from: 24678937

14. Makkar RR, Fontana GP, Jilaihawi H, Kapadia S, Pichard AD, Douglas PS, et al. Transcatheter aortic-valve replacement for inoperable severe aortic stenosis. N Engl J Med. 2012 May 3;366(18):1696–704. Available from: doi: 10.1056/NEJMoa1202277 22443478

15. Noble S, Roffi M. Overcoming the challenges of the transfemoral approach in transcatheter aortic valve implantation. Interv Cardiol Rev.2013 Aug;8(2):131–4. Available from:

16. Avanzas P, Munoz-Garcia AJ, Segura J, Pan M, Alonso-Briales JH, Lozano I, et al. Percutaneous implantation of the core valve self-expanding aortic valve prosthesis in patients with severe aortic stenosis: early experience in Spain. Rev Esp Cardiol. 2010 Feb;63(2):141–8. Available from: doi: 10.1016/s1885-5857(10)70031-1 20109412

17. Martinez-Selles M, Bramlage P, Thoenes M, Schymik G. Clinical significance of conduction disturbances after aortic valve intervention: current evidence. Clin Res Cardiol.2015 Jan 4;104(1):1–12. Available from: doi: 10.1007/s00392-014-0739-6 24990451

18. Seiffert M, Bader R, Kappert U, Rastan A, Krapf S, Bleiziffer S, et al. Initial German experience with transapical implantation of a second-generation transcatheter heart valve for the treatment of aortic regurgitation. JACC Cardiovasc Interv.2014 Oct;7(10):1168–74. Available from: doi: 10.1016/j.jcin.2014.05.014 25129672

19. Eisen A, Shapira Y, Sagie A, Kornowski R. Infective endocarditis in the transcatheter aortic valve replacement era: comprehensive review of a rare complication. Clin Cardiol.2012 Nov;35(11):E1–5. Available from: doi: 10.1002/clc.22052 22990884

20. Ben-Shoshan J, Amit S, Finkelstein A. Transcatheter aortic valve implantation infective endocarditis: current data and implications on prophylaxis and management.Curr Pharm Des.2016;22(13):1959–64. Available from: doi: 10.2174/1381612822666151229102028 26710943

21. Loh PH, Bundgaard H, Sondergaard L. Infective endocarditis following transcatheter aortic valve replacement: Diagnostic and management challenges. Catheter Cardiovasc Interv.2013 Mar;81(4):623–7. Available from: doi: 10.1002/ccd.24368 22431450

22. Martinez-Selles M, Bouza E, Diez-Villanueva P, Valerio M, Farinas MC, Munoz-Garcia AJ, et al. Incidence and clinical impact of infective endocarditis after transcatheter aortic valve implantation. EuroIntervention. 2016 Feb;11(10):1180–7. Available from: doi: 10.4244/EIJY15M02_05 25671426

23. Amat-Santos IJ, Messika-Zeitoun D, Eltchaninoff H, Kapadia S, Lerakis S, Cheema AN, et al. Infective endocarditis after transcatheter aortic valve implantation: results from a large multicenter registry. Circulation. 2015 May 5;131(18):1566–74. Available from: 25753535

24. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med.2011 Jun 9;364(23):2187–98. Availablefrom: 21639811

25. Thomas M, Schymik G, Walther T, Himbert D, Lefevre T, Treede H, et al. One-year outcomes of cohort 1 in the Edwards SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) registry: the European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve. Circulation. 2011 Jul 26;124(4):425–33. Available from: doi: 10.1161/CIRCULATIONAHA.110.001545 21747054

26. Amat-Santos IJ, Ribeiro HB, Urena M, Allende R, Houde C, Bedard E, et al. Prosthetic valve endocarditis after transcatheter valve replacement: a systematic review. JACC Cardiovasc Interv. 2015 Feb;8(2):334–46. Available from: doi: 10.1016/j.jcin.2014.09.013 25700757

27. Olsen NT, De Backer O, Thyregod HGH, Vejlstrup N, Bundgaard H, Sondergaard L, et al. Prosthetic valve endocarditis after transcatheter aortic valve implantation. Circ Cardiovasc Interv.2015 Apr;8(4):pii:e001939. Available from: doi: 10.1161/CIRCINTERVENTIONS.114.001939 25873728

28. Regueiro A, Linke A, Latib A, Ihlemann N, Urena M, Walther T, et al. Association between transcatheteraortic valve replacement and subsequent infective endocarditis and in-hospital death. JAMA.2016 Sep 13;316(10):1083. Availablefrom: doi: 10.1001/jama.2016.12347 27623462

29. Spartera M, Ancona F, Barletta M, Rosa I, Stella S, Marini C, et al. Echocardiographic features of post-transcatheter aortic valve implantation thrombosis and endocarditis. Echocardiography.2018 Mar; 35(3):337–45. Available from: 29267985

30. Chourdakis E, Koniari I, Hahalis G, Kounis NG, Hauptmann KE. Endocarditis after transcatheter aortic valve implantation: a current assessment. J GeriatrCardiol. 2018;15:61–5. doi: 10.11909/j.issn.1671-5411.2018.01.003 29434627

31. Habib G. Infective endocarditis after transcatheter aortic valve replacement: the worst that can happen. JAHA. 2018;7:e10287.

32. Qureshi K, Rajah A. Septic shock: a review article. BJMP. 2008;1(2):7–12.

33. Latib A, Naim C, De Bonis M, Sinning JM, Maisano F, Barbanti M, et al. TAVR-associated prosthetic valve infective endocarditis: results of a large, multicenter registry. J Am Coll Cardiol.2014 Nov;64(20):2176–8. Available from: doi: 10.1016/j.jacc.2014.09.021 25457406

34. Puls M, Eiffert H, Hunlich M, Schondube F, Hasenfub G, Seipelt R, et al. Prosthetic valve endocarditis after transcatheter aortic valve implantation:the incidence in a single-centre cohort and reflections on clinical, echocardiographic and prognostic features. EuroIntervention.2013 Apr 22;8(12):1407–18. Available from: doi: 10.4244/EIJV8I12A214 23015071

35. Gallouche M, Barone-Rochette G, Pavese P, Bertrand B, Vanzetto G, Bouvaist H, et al. Incidence and prevention of infective endocarditis and bacteremia after transcatheter aortic valve implantation in a French university hospital: a retrospective study. J Hosp Infect.2018 May;99(1):94–7. Available from: doi: 10.1016/j.jhin.2017.11.013 29191610

36. Kosek M, Witkowski A, Dąbrowski M, Jastrzębski J, Michalowska I, Chmielak Z, et al. Transcatheter aortic valve implantation in patients with bicuspid aortic valve: a series of cases. KardiologiaPolska.2015;73(8):627–36. doi: 10.5603/KP.a2015.0068 26314883

37. Doss M, Buhr EB, Martens S, Moritz A, Zierer A. Transcatheter-based aortic valve implantations at midterm: what happened to our initial patients? Ann Thorac Surg.2012 Nov 1;94(5):1400–6. Available from: doi: 10.1016/j.athoracsur.2012.05.051 22776084

Článek vyšel v časopise


2020 Číslo 1
Nejčtenější tento týden